Site Search
Professionals 118 results
Capabilities 44 results
Practice Area
Practice Area
Class Actions & Group Litigation
Winston has developed a consistent record of success handling class action cases in state and federal courts. The practice is anchored by seasoned class action lawyers, many of whom have been recognized by Chambers USA and other ranking organizations as being top practitioners in their field. Our clients rely on us to steer them through class action matters by drawing on the firm’s significant experience in resolving complex litigation using creative and aggressive arguments, across a broad range of class, collective, coordinated, and mass actions, as well multidistrict litigation. We also have succeeded at trial in several class actions—a rare occurrence.
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Experience 109 results
Experience
|July 30, 2025
Represent Norman W. Fries, Inc. d/b/a Claxton Poultry Farms in a series of 15+ antitrust class actions consolidated in the Northern District of Illinois and brought by plaintiffs who allege that Claxton and the nation’s other largest poultry producers conspired to fix the price of broiler chickens in a scheme from 2008 to 2016 that raised the price for broiler chickens by artificially reducing supply.
Experience
|July 17, 2025
D. Boral Capital Closes US$15M Robot Consulting IPO
Winston & Strawn LLP represented D. Boral Capital LLC and Craft Capital Management LLC in connection with the US$15M initial public offering of American Depositary Shares (ADSs) of Robot Consulting Co., Ltd. The offering consisted of 3,750,000 ADSs priced at $4.00 per ADS, and the company’s ADSs began trading on the Nasdaq Capital Market under the ticker symbol “LAWR” on July 17, 2025.
Experience
|May 27, 2025
PicoCELA Inc. Closes $1.8 Public Offering
Winston & Strawn represented Revere Securities LLC acted as the lead placement agent in connection with PicoCELA, Inc. in the closing of its public offering of 6,100,000 American Depositary Shares ("ADSs") at a public placement price of $0.30 per ADS. PicoCELA, Inc. received an aggregate gross proceeds of $1.83 million before deducting placement agent commission and other offering expenses. Each ADS represents one common share of the Company.
Insights & News 831 results
Sponsorship
|October 19, 2025
Winston & Strawn Sponsors The 2025 National Summit for Middle Market Funds
Winston & Strawn is proud to be an elite sponsor of The 2025 National Summit for Middle Market Funds, the premier event for lower middle market networking and fundraising.
Competition Corner
|September 30, 2025
|5 Min Read
Enforcement Priorities of the FTC and DOJ—Insights from Recent Antitrust Conferences
The landscape of antitrust enforcement in the United States continues to undergo a significant transformation, as highlighted by recent remarks from leaders at both the Federal Trade Commission and the Department of Justice.
Client Alert
|September 22, 2025
|1 Min Read
Interest Rates Fall for SBICs: September 2025 Standard Debenture Pooling
The September 2025 pooling of Small Business Investment Company (SBIC) standard debentures was priced at 4.532%. This most recent semiannual pricing of SBIC standard debentures reflected a decrease from the rate set in March 2025 of 4.963%. This is the third consecutive semiannual pricing below 5.0% and is the second-lowest pricing since 2022.
Other Results 36 results
Site Content
What Is the Price Range in an IPO?
The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price.
Site Content
Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA).
Site Content
Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table.